Cannabis Science Announces the Appointment Of Robert Kane Formerly Of Stifel Nicolaus for Investor Relations Management
September 19, 2011
Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that Robert Kane, formerly of Stifel Nicolaus (NYSE:SF), has been retained by Cannabis Science in the capacity of Investor Relations Management to increase Company exposure, access to capital, and ultimately increase shareholder value.
Robert Kane, studied at Elon University in Elon, North Carolina as an Isabella Cannon Leadership fellow, where he studied economics and accounting. Robert has over 20 years of experience in creating sound business models and began working in 1998 for Ryan, Beck & Co which was acquired by Stifel Nicolaus (NYSE: SF) Robert spent over 11 years in the Private Client Group focusing on small and mid-cap regional banks and thrifts and participating in syndicated and equity offerings and conversions. Mr. Kane has built a reputation for astute business development and management leadership in both for-profit and non-profit organizations.
Dr. Robert Melamede, President & CEO of Cannabis Science Inc., Stated, “Our shareholders are very important to us and our decision to bring in someone reputable like Robert Kane, with over a decade of previous investment experience from one of the top 10 firms in the nation, felt like the right thing to do at this juncture to build company exposure, access capital, and ultimately increase shareholder value.”
On December 31, 2009, Robert left the banking world, and started the firm Cannabis Consulting Inc. in May of 2010. Cannabis Consulting Inc.’s mission is to establish the Medical Cannabis Industry as a viable investment alternative for all investors. This is done through the writing of business plans for small and mid-size businesses in the medical marijuana industry and advising those companies, in an Investor Relations capacity, on how ancillary medical marijuana businesses can access financial and capital markets. This has led to the creation of The Kaneabis Fund, the industry’s first medical cannabis private equity fund which is currently seeking seed funding up to $36 million with a goal of $132 million.
Robert Kane said, “Investors have few choices when it comes to investing in the Medical Cannabis Industry. This is not a ‘let’s get high industry’. The science and medicine is the true value in the Medical Cannabis Investment. This is evidenced by the success of GW Pharmaceuticals’ Sativex® product. Cannabis Science is a conservative, well-managed company with real long term value if you understand the science and medicine side of this industry. I am proud to be working with Cannabis Science to increase shareholders value for an organization that is truly on the front lines of this science of medicine.”
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
View full post on News Releases